Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|January 19, 2017
Bio-Optronics Introduces CTMS Upgrade
Advertisement
Rochester, NY – Bio-Optronics Inc. is proud to announce the latest release of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. All patient management information has been condensed to a single page, maximizing usability and improving efficiency significantly for users – a first in the CTMS industry. With a configurable and customizable interface, organizations can view the patient information that is the most important to them.
This enhanced patient management solution introduces a variety of features to improve the everyday usability of Clinical Conductor. Users have access to multiple checklists, including patient and visit checklists, providing accountability for successfully complete patient visits. Patient payment information is also accessible on the patient management homepage, providing patients with a quick and easy stipend. The patient management homepage condenses patient information on a single platform; by utilizing the alerts, auto-refresh and configurable action column features, users can complete their tasks with ease.
“This latest update is truly remarkable; by providing our users with a simplified solution to their patient management tasks, we improve the way they progress through their clinical trials and boost the quality of care provided to their patients in the process,” says Steve Bailey, Vice President of Clinical Conductor CTMS.
Clinical Conductor CTMS is committed to maximizing efficiency and offering features to its users that are aligned to their workflows, and designed to simplify their daily activities. The patient management homepage, with its visually appealing and customizable interface, provides a space for all visit-related information to be easily accessible.
The new patient management functionality is now available to all Clinical Conductor Site users.
About Bio-Optronics
Bio-Optronics is a leading healthcare information technology company, focusing specifically on workflow optimization. Our mission is to develop and deploy software products and services to help healthcare professionals enhance quality, productivity, patient and staff satisfaction. Since 1985, Bio-Optronics has created unique and innovative software solutions for the US Department of Veterans Affairs (VA), hospitals, health networks, medical practices, academic medical centers, imaging centers, and all participants in the clinical trial enterprise.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5